Literature DB >> 16792584

Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children.

B Niggemann1, L Jacobsen, S Dreborg, H A Ferdousi, S Halken, A Høst, A Koivikko, D Koller, L A Norberg, R Urbanek, E Valovirta, U Wahn, C Möller.   

Abstract

BACKGROUND: A 3-year course of specific immunotherapy (SIT) in children with hay fever to grass and/or birch pollen significantly reduced the risk of developing asthma. To investigate the long-term preventive effect, we performed a follow up--2 years after termination of immunotherapy.
METHODS: A total of 183 children, aged 6-14 years with grass and/or birch pollen allergy could be investigated 2 years after discontinuation of SIT or no treatment. Conjunctival provocation tests (CPTs) and methacholine bronchial provocation tests were carried out during the season and winter after 5 years. The development of asthma was assessed by clinical evaluation.
RESULTS: The significant improvement in hay fever and CPT results observed after 3 years of SIT persisted at the 5-year follow-up. No difference in bronchial responsiveness to methacholine was found after 5 years because of spontaneous improvement during the follow-up period in the control patients. The immunotherapy-treated children had significantly less asthma after 5 years as evaluated by clinical symptoms [odds ratio 2.68 (1.3-5.7)] in favor of SIT for prevention of development of asthma and significantly less patients reported an increase in asthma scores (P < 0.01).
CONCLUSION: Immunotherapy for 3 years with standardized allergen extracts of grass and/or birch shows long-term clinical effect and preventive effect on development of asthma in children with seasonal rhinoconjunctivitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16792584     DOI: 10.1111/j.1398-9995.2006.01068.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  54 in total

1.  [Prevention of respiratory tract diseases].

Authors:  J C Virchow
Journal:  Internist (Berl)       Date:  2008-02       Impact factor: 0.743

Review 2.  Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review.

Authors:  Julia M Kim; Sandra Y Lin; Catalina Suarez-Cuervo; Yohalakshmi Chelladurai; Murugappan Ramanathan; Jodi B Segal; Nkiruka Erekosima
Journal:  Pediatrics       Date:  2013-05-06       Impact factor: 7.124

Review 3.  Early identification of atopy in the prediction of persistent asthma in children.

Authors:  Peter D Sly; Attilio L Boner; Bengt Björksten; Andy Bush; Adnan Custovic; Philippe A Eigenmann; James E Gern; Jorrit Gerritsen; Eckard Hamelmann; Peter J Helms; Robert F Lemanske; Fernando Martinez; Soren Pedersen; Harald Renz; Hugh Sampson; Erika von Mutius; Ulrich Wahn; Patrick G Holt
Journal:  Lancet       Date:  2008-09-20       Impact factor: 79.321

Review 4.  Preventing progression of allergic rhinitis to asthma.

Authors:  Jaymin B Morjaria; Massimo Caruso; Emma Rosalia; Cristina Russo; Riccardo Polosa
Journal:  Curr Allergy Asthma Rep       Date:  2014-02       Impact factor: 4.806

Review 5.  Current and future management of the young child with early onset wheezing.

Authors:  Allison J Burbank; Stanley J Szefler
Journal:  Curr Opin Allergy Clin Immunol       Date:  2017-04

Review 6.  Treatment of Allergic Rhinitis as a Strategy for Preventing Asthma.

Authors:  Jaymin B Morjaria; Massimo Caruso; Rosalia Emma; Cristina Russo; Riccardo Polosa
Journal:  Curr Allergy Asthma Rep       Date:  2018-03-24       Impact factor: 4.806

Review 7.  Sublingual immunotherapy in pediatric allergic rhinitis and asthma: efficacy, safety, and practical considerations.

Authors:  Linda Cox
Journal:  Curr Allergy Asthma Rep       Date:  2007-11       Impact factor: 4.806

8.  A prospective study on the association between hay fever among children and incidence of asthma in East Germany.

Authors:  Peter Rzehak; Yvonne Schoefer; H-Erich Wichmann; Joachim Heinrich
Journal:  Eur J Epidemiol       Date:  2007-11-06       Impact factor: 8.082

Review 9.  [Costs of allergic diseases and saving potential by allergen-specific immunotherapy : A personal assessment].

Authors:  L Klimek; A M Chaker; R Mösges
Journal:  HNO       Date:  2017-10       Impact factor: 1.284

10.  Cytotoxic T lymphocyte antigen 4-immunoglobulin G is a potent adjuvant for experimental allergen immunotherapy.

Authors:  H Maazi; S Shirinbak; L E den Boef; F Fallarino; C Volpi; M C Nawijn; A J M van Oosterhout
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.